AzTrials
AzTrials

Periodontal and Endodontic LesionNCT03169946

Chlorhexidine-Metronidazole Combination as an Intracanal Medicament on Periodontal Healing

A study testing RCT with CHX-MTZ,OFD and RCT with CHX,OFD in people with Periodontal and Endodontic Lesion, run by Postgraduate Institute of Dental Sciences Rohtak.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Considering the beneficiary properties of both Chlorhexidine (CHX) and Metronidazole (MTZ) such as property of substantivity and diffusion of these drugs on the external surfaces through the anatomical communication channels in between the root canals and periodontium, may be utilized as an alternative approach for… Read more about this study

Who is it for?
Ages 18 to 55 yearsHealthy volunteers can take part
Conditions the study is for
Periodontal and Endodontic Lesion
What is being tested?
RCT with CHX-MTZ,OFD and RCT with CHX,OFD
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
36 participants
Where
No sites listed yet
Study dates
14 Oct 2016to Sep 2017
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 55 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Patients of age between 18-55 years with generalized chronic periodontitis will be enrolled, having at least one tooth with concurrent endodontic periodontal lesion with communication including following features:
  • a clinical and radiographic diagnosis of concurrent endodontic periodontal lesion
  • Wide base pocket, deep probing pocket depth
  • Non vital tooth on the basis of pulp sensibility tests along with periapical radiolucency
  • Radiographic alveolar bone (marginal bone) destruction with apical communication
  • Patients of generalized chronic periodontitis will be selected on the basis of Armitage classification of periodontal diseases and conditions [≥30% sites involved with clinical attachment level (CAL) 1-2mm (mild) or 3-4mm (moderate) or ≥5mm (severe)]
  • Patients should have more than 20 teeth in their oral cavity excluding third molars.

Who cannot join

  • Systemic illness known to affect the periodontium or outcome of periodontal therapy.
  • Patient taking medications such as corticosteroids, calcium channel blockers and anticoagulant therapy, which are known to interfere periodontal wound healing or patient on long term NSAID therapy or bisphosphonates.
  • Patients allergic to medication (chlorhexidine, local anaesthetic, antibiotics, NSAID).
  • Patients with acute symptoms.
  • Pregnant or lactating females.
  • Smokers (current and past) and tobacco chewers.
Show all 15Show fewer
  • Grade 3 mobile teeth.
  • Unrestorable tooth.
  • Root resorption.
  • Fractured/perforated roots.
  • Developing permanent tooth.
  • Abutments.
  • Previously root canal filled tooth.
  • Patients with aggressive periodontitis
  • History of periodontal treatment within 6 months prior to study.

About this study

Official title: Effects of Chlorhexidine-Metronidazole Combination as an Intracanal Medicament on Periodontal Healing in Concurrent Endodontic Periodontal Lesions With Communication: A Randomized Controlled Clinical Study

Considering the beneficiary properties of both Chlorhexidine (CHX) and Metronidazole (MTZ) such as property of substantivity and diffusion of these drugs on the external surfaces through the anatomical communication channels in between the root canals and periodontium, may be utilized as an alternative approach for the delivery of drug ( intracanal medicament) in the deep periodontal pockets in concurrent endodontic- periodontic lesion with communication lesions. Thus the aim of study is to conduct a prospective randomized controlled clinical trial to evaluate and compare the effects of CHX-MTZ combination with chlorhexidine alone as an intracanal medicament on periodontal healing in concurrent endodontic- periodontic lesion with communication.

Read the detailed description

INTRODUCTION

The pulp tissue within the tooth and surrounding periodontium are interrelated to each other due to structural, functional and microbiological similarities. Cross infection of bacterial colonies take place in between these sites through dentinal tubules, apical foramen, lateral and accessory canals.Concurrent endodontic- periodontic lesions are those lesions where both endodontic and periodontal diseases occurring at same time in relation to single tooth.

Endodontic infection present in tooth is responsible for more bone loss, attachment loss and results in impaired healing of periodontium and vice versa.

Complete elimination of microorganisms from infected root canal is very challenging and complicated task. It has been reported that bacteria may survive within the root canal even after chemomechanical preparation, these remaining bacteria again multiply within the root canal. So, intracanal medicament is used as an adjunct to mechanical preparation in disinfection of root canal system.

Chlorhexidine (CHX) is widely used as an intracanal medicament because of its high antimicrobial action, against gram positive and gram negative bacteria.

Antibacterial substantivity of CHX is significantly higher than other medicaments. Various microbiological studies found the reduction in bacterial adherence, lager zones of microbial inhibition after application of CHX as an intracanal medicament. Raheja et al described that 2% CHX gel as an intracanal medicament provide substantive antibacterial activity for sufficiently long periods of time and helps in better healing of endodontic periodontal lesions without communication in their clinical study. Although, CHX is very effective as an intracanal medicament, but can't be used as an final irrigant due to it allergic, hypersensitive reaction, precipitation formation with sodium hypochlorite, EDTA, saline and ethanol and its inability to dissolve necrotic tissue.

In endodontic and periodontal treatment, antibiotics are valuable adjunctive for management of bacterial infections. Local application of antibiotics is considered more effective than systemic administration because of potential risk of adverse effects associated with systemic application.Metronidazole(MTZ) is nitroimidazole compound having broad antibacterial spectrum of bactericidal action mainly against anaerobic microorganisms. MTZ is given along with ciprofloxacin and minocycline as a combination in 3M antibiotic paste in the form of intracanal medicament. Kargul et al in a clinical study showed that there was no abscess formation and pathologic mobility when metronidazole is used as an intracanal medicament.Observations based on in vitro study showed that MTZ-CHX combination was better than calcium hydroxide as an intracanal medicament against E.faecalis.

Keeping in mind the above observations and considering the beneficiary properties of both CHX and MTZ such as property of substantivity and diffusion of these drugs on the external surfaces through the anatomical communication channels in between the root canals and periodontium, may be utilized as an alternative approach for the delivery of drug ( intracanal medicament) in the deep periodontal pockets in these lesions. Thus the aim of study is to conduct a prospective randomized controlled clinical trial to evaluate and compare the effects of CHX-MTZ combination with chlorhexidine alone as an intracanal medicament on periodontal healing in concurrent endodontic- periodontic lesion with communication.

MATERIAL AND METHOD

This study will be conducted in Department of Periodontics and Oral Implantology in collaboration with Department of Conservative Dentistry and Endodontics, Post Graduate Institute of Dental Sciences (PGIDS), Rohtak. The study protocol is according to the ethical standards of Helinski declaration 1975 as revised in 2013.

STUDY POPULATION

Patients will be recruited from regular outpatient department of the periodontics, endodontics and oral medicine PGIDS, Rohtak. The study will be conducted as follows:

Interventional study: This randomized controlled clinical trial will include minimum 36 patients which will be further divided into two groups.

Test Group (n≈ 18)

Treatment involves endodontic treatment using intracanal medicament (chlorhexidine metronidazole combination) along with open flap debridement.

Positive Control Group (n≈ 18)

Treatment involves endodontic treatment using chlorhexidine alone as an intracanal medicament along with surgical periodontal therapy in form of open flap debridement.

METHODOLOGY

Patients will be randomly allocated to control and test groups. The study will be conducted as follows:

  1. Presurgical therapy: which will be including
  • Oral hygiene instructions and patient motivation
  • Full mouth supragingival and subgingival scaling and root planning with ultrasonic scaler (EMS Piezon 250, Switzerland), hand scaler and curettes (Hu-Friedy) will be completed in two sessions.
  • Root canal therapy will be initiated in both the groups.
  • In Test group- Metronidazole-chlorhexidine combination (metronidazole-15mg, chlorhexidine gluconate-0.5%w/w)as an intracanal medicament and in positive control group 2% chlorhexidine gel will be placed in root canals. In both groups, total duration for medicament placement will be of 4 weeks.
  1. Surgical therapy : After 2 weeks of intracanal medicament placement in both test group and in control group, periodontal surgical procedure in the form of open flap debridement will be performed in both groups.
  2. At the time of periodontal surgical procedure, intracanal medicament will be replaced with fresh one and will be remained in the root canals further for 2 weeks (medicament placed for total duration of 4 weeks), after that obturation will be done in both groups.

A probing stent will be fabricated for every patient irrespective of the group, relative to which attachment level, pocket probing depth will be measured.

CLINICAL PARAMETERS

  1. Full mouth indices to be recorded at baseline
  • Plaque index(PI)
  • Gingival index(GI)
  • Bleeding on probing(BOP)
  • Probing Pocket depth(PPD)
  • Clinical attachment loss(CAL)
  1. Site specific indices
  • Plaque index(PI)
  • Gingival index(GI)
  • Relative Probing Pocket depth(RPPD)
  • Relative Attachment Loss (RAL)
  • Bleeding on probing (BOP)
  • Tooth mobility
  • Relative Gingival Marginal Level (RGML)

Using UNC 15 periodontal probe at 6 sites (mesiobuccal, distobuccal, mesiolingual, distolingual, and median points at buccal and at lingual aspects) per tooth except 3 rd molars for PPD, BOP, GML and CAL while 4 surfaces (mesial, distal, median points at buccal and lingual aspect) will be measured for PI, GI.

Customized bite blocks and parallel angle technique will be used to obtain radiographs.

Clinical parameters will be recorded at baseline, 2 weeks of endodontic treatment and at 3 months, 6 months of periodontal surgery.

PERIODONTAL NON SURGICAL PROCEDURE

This involves supragingival and subgingival scaling and root planing to be performed with ultrasonic scaler, hand scaler and curette and will be completed in minimum two sessions along with patient education and motivation.

ENDODONTIC PROCEDURE

After achieving local anaesthesia, access opening will be made with the help of round bur. Then the root canal will be thoroughly debride followed by copious irrigation and subsequently prepared with the help of endo files. After preparation of the canal, chlorhexidine- metronidazole combination as an intracanal medicament will be placed in test group, chlorhexidine medicament in positive control group and access cavity will be sealed with suitable sealer and medicament left inside for the above mentioned time period. Obturation will be performed with gutta percha and zinc oxide eugenol based sealer.

PERIODONTAL SURGICAL PROCEDURE

After administration of local anaesthesia, buccal and lingual/palatal intracrevicular incision will be made and mucoperiosteal flaps will be reflected including at least one tooth ahead and another behind the tooth. Meticulous defect debridement and root planing will be carried out using area specific curettes and scalers to remove all the granulation tissue. After instrumentation, the root surfaces will be washed with saline solution in attempt to remove any remaining detached fragments from the defect and surgical field. After debridement mucoperiosteal flaps will be repositioned and secured by using 3-0 non absorbable black silk surgical suture. The surgical area will be protected and covered with periodontal dressing and post operative instructions will be given.

POST OPERATIVE CARE

  • Suitable antibiotics and analgesics will be prescribed for 5 days.
  • Periodontal dressing and sutures will be removed after 1 week.
  • Instructions will be given for gentle brushing with soft brush and reinstructed for proper oral hygiene postoperatively and will be examined weekly for up to 1 month after surgery and again at 3 and 6 months.
Being tested
RCT with CHX-MTZ,OFD, RCT with CHX,OFD

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • RCT with CHX-MTZ,OFDProcedure or surgery

    Endodontic treatment using chlorhexidine metronidazole combination as an intracanal medicament along with open flap debridement .

  • RCT with CHX,OFDProcedure or surgery

    Endodontic treatment using chlorhexidine as an intracanal medicament along with surgical periodontal therapy in form of open flap debridement.

Study groups in NCT03169946
Study groupRoleWhat they receive
Test GroupActive comparatorEndodontic treatment using chlorhexidine metronidazole combination as an intracanal medicament along with open flap debridement (RCT with CHX-MTZ,OFD).
Receives: Procedure: RCT with CHX-MTZ,OFD
Positive Control Group :Active comparatorEndodontic treatment using chlorhexidine as an intracanal medicament along with surgical periodontal therapy in form of open flap debridement(RCT with CHX,OFD).
Receives: Procedure: RCT with CHX,OFD

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. PPD

    Probing pocket depth

    Measured: 6 and half months

  2. CAL

    Clinical attachment loss

    Measured: 6 and half months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 May 2017
  2. Study start14 Oct 2016
  3. Primary completionSep 2017 (estimated)
  4. Study completionSep 2017 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
36 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03169946
Sponsor's protocol ID
kirtika perio 2015
Status last verified
May 2017
First submitted
24 May 2017
Last updated
30 May 2017
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes

Questions about this trial

What is this clinical trial studying?

A study testing RCT with CHX-MTZ,OFD and RCT with CHX,OFD in people with Periodontal and Endodontic Lesion, run by Postgraduate Institute of Dental Sciences Rohtak.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 30 May 2017. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

PPD (time frame: 6 and half months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 May 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in